These results indicate that Chel A treatment leads to autophagy-mediated PHLPP2 protein degradation, and in turn results in JNK/C-Jun phosphorylation and activation, consequently leading to apoptosis of human bladder cancer cells, as briefly summarized in Figure 5H. The gene discussed is JUN; the disease is urinary bladder carcinoma.